A Validation Cohort for ACLF Diagnosis and Prognosis

CompletedOBSERVATIONAL
Enrollment

1,370

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

April 21, 2020

Study Completion Date

July 31, 2020

Conditions
Liver Failure, Acute on ChronicLiver Dysfunction
Interventions
OTHER

Standary therapy

Standary therapy for chronic liver disease with ALI and/or AD

Trial Locations (12)

100015

Ditan Hospital of integrated traditional Chinese and Western Medicine Center, Beijing

130021

The First Affiliated Hospital of Jilin University, Changchun

200001

Renji hospital of Shanghai Jiao Tong University School of Medical, Shanghai

200083

Shanghai Public Health Clinical Center, Shanghai

310003

The First Affiliated Hospital of Zhejiang University, Hangzhou

400038

Southwest Hospital of Third Military Medical University, Chongqing

410008

Xiangya hospital of Central South University, Changsha

430022

Wuhan Union Hospital of Huazhong University of Science and Technology, Wuhan

442000

Taihe Hospital, Shiyan

450003

Henan Provincial People's Hospital, Zhengzhou

510515

Southern hospital infection department, Guangzhou

830054

Infectious Disease Center, The First Teaching Hospital of Xinjiang Medical University, Ürümqi

All Listed Sponsors
lead

Hai Li

OTHER

NCT03641872 - A Validation Cohort for ACLF Diagnosis and Prognosis | Biotech Hunter | Biotech Hunter